Apricus Biosciences (APRI) announced that it has entered into a common stock purchase agreement with Aspire Capital Fund. Aspire will complete an initial purchase of ~2.5M shares of common stock for proceeds of $1M (~$0.40/share) and has committed to purchase up to $6M in additional shares over the next 24 months. According to the terms of the agreement, Apricus will control the timing and amount of any sale of shares of common stock to Aspire Capital. Aspire Capital has no right to require any sales by Apricus but is obligated to make purchases as Apricus directs. Apricus may terminate the purchase agreement at any time, at its discretion, without any additional cost or penalty.